title: Utility of patch testing for patients with drug eruption.
abstract: BACKGROUND
  Patch testing is less dangerous than oral provocation testing for identification of the causative drug for patients with drug eruption; however, its usefulness for such identification is controversial.
  
  
  OBJECTIVE
  To clarify the rates of positive patch testing for patients with drug eruption, classified by causative drugs and clinical features.
  
  
  METHODS
  We analysed results during the period 1990-2010 for 444 patients (151 men, 293 women; mean ± SD age 49.9 ± 18.6 years) who were tested for drug eruption. In the patient group, there were 309 people (69.1%) with maculopapular eruption and 31 (6.9%) with severe drug eruption. The test materials were applied to the back and left for 2 days under occlusion, then results were assessed by the International Contact Dermatitis Research Group (ICDRG) scoring system 3 days after application. Reactions of + to +++ were regarded as positive.
  
  
  RESULTS
  Of the 444 patients, 100 (22.4%) had a positive patch test result to a suspected drug. Positive rates were 23.6% and 20.0% for maculopapular eruption and fixed drug eruption, respectively. The class of materials to which most patients reacted positively was contrast medium (n = 53; 41.1%), followed by drugs acting on the central nervous system (n = 18; 28.6%). In the latter group, 16 of the 18 patients were positive to antiepileptics.
  
  
  CONCLUSIONS
  Positive rates depend on the causative drug rather than the clinical features of the drug eruption. Patch testing is useful when contrast medium or antiepileptics are suspected to be the causative drugs. However, standardization of patch test materials and method of reading is needed, as well as guidelines regarding when testing should be performed. Although patch testing for drug eruption has significant potential, it requires further validation.
authors.affiliation: Division of Dermatology, Showa University Fujigaoka Hospital, Kanagawa, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Ohtoshi
authors.forename: Y
authors.initials: Y
authors.lastname: Kitami
authors.forename: H
authors.initials: H
authors.lastname: Sueki
authors.forename: T
authors.initials: T
authors.lastname: Nakada
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D003875:Drug Eruptions / Q000175:diagnosis*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010328:Patch Tests / Q000379:methods / Q000592:standards*; D055815:Young Adult